Abstract
Global healthcare expenditure has increased substantially in recent years. Due to budget constraints and limited healthcare resource availability, not all approved new health technologies (HTs) are reimbursed across European countries, limiting patient access to innovative healthcare. In Europe, various country-specific pharmacoeconomics (PE) guidelines are followed to optimize costs and benefits of new HTs allowing appropriate resource allocation, thereby, maximizing net health benefits. This study aims to identify similarities and differences in PE guidelines across European countries.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
